Top

Clinical and Translational Oncology

Published in:

01-10-2014 | Research Article

Meta-analysis of the cytotoxic T-lymphocyte antigen 4 gene +6230G/A polymorphism and cancer risk

Authors: H.-Y. Zhao, H.-X. Duan, Y. Gu

Published in: Clinical and Translational Oncology | Issue 10/2014

Abstract

Objectives

Cytotoxic T-lymphocyte antigen-4 (CTLA4, CD152) is one of the most fundamental immunosuppressive cytokines that inhibits T-cell activation and terminates the T-cell response by blocking signals stimulated via CD28. A number of studies have assessed the association between CTLA-4 +6230G/A polymorphism and cancer risk. However, the results remain controversial.

Methods

In the present study, we performed a meta-analysis to derive a more precise estimation of the relationship. A comprehensive literature search was performed using the PubMed database for relevant articles published (updated to November 21, 2013). Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of the association.

Results

A total of 13 articles with 14 studies were selected for this meta-analysis, including 4,489 cases and 4,715 controls. Combined analysis revealed no associations between CTLA-4 +6230G/A polymorphism and cancer risk. However, in stratified analysis by cancer type, we found that CTLA-4 +6230G/A polymorphism was associated with the risk of breast cancer (AA vs. AG + GG: OR = 0.77, 95 % CI 0.60–0.97, P = 0.03; AA vs. GG: OR = 0.66, 95 % CI 0.46–0.95, P = 0.02) and cervical cancer (AA vs. AG + GG: OR = 0.56, 95 % CI 0.42–0.75, P < 0.01). Additionally, in subgroup analysis based on ethnicity, significant association was also found between the CTLA-4 +6230G/A polymorphism and cancer risk in the Asian population (AA vs. AG + GG: OR = 0.71, 95 % CI 0.59–0.84, P < 0.01).

Conclusion

This meta-analysis indicates that CTLA-4 +6230G/A polymorphism may be associated with a decreased risk of breast cancer and cervical cancer in Chinese population.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef

Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4:850–60.PubMedCrossRef

Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001;2:145–52.PubMedCrossRef

Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006;24:65–97.PubMedCrossRef

Scheipers P, Reiser H. Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci USA. 1998;95:10083–8.PubMedCrossRefPubMedCentral

Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol. 2005;6:1207–10.PubMedCrossRef

Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, et al. Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat. 2004;86:1–7.PubMedCrossRef

Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, et al. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2006;24:3483–9.PubMedCrossRef

Chuang WY, Strobel P, Gold R, Nix W, Schalke B, Kiefer R, et al. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol. 2005;58:644–8.PubMedCrossRef

10.

Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68:698–704.PubMedCrossRef

11.

Karabon L, Pawlak E, Tomkiewicz A, Jedynak A, Passowicz-Muszynska E, Zajda K, et al. CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer. Hum Immunol. 2011;72:947–54.PubMedCrossRef

12.

Karabon L, Pawlak-Adamska E, Tomkiewicz A, Jedynak A, Kielbinski M, Woszczyk D, et al. Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a Polish population. Pathol Oncol Res. 2012;18:219–26.PubMedCrossRefPubMedCentral

13.

Li D, Zhang Q, Xu F, Fu Z, Yuan W, Pang D. Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of northeast China. Mol Cell Biochem. 2012;364:283–90.PubMedCrossRef

14.

Li H, Fu ZK, Wang LH, Li DL, Wu N, Zhang J, et al. Association of cytotoxic T lymphocyte antigen-4 gene polymorphisms with susceptibility to breast cancer. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24:282–4.PubMed

15.

Liu J, Song B, Wang T, Liu Y, Hao J, Yu J. Genetic variations in CTLA-4, TNF-alpha, and LTA and susceptibility to T-cell lymphoma in a Chinese population. Cancer Epidemiol. 2013;37(6):930–4.PubMedCrossRef

16.

Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30:1051–5.PubMedCrossRef

17.

Su TH, Chang TY, Lee YJ, Chen CK, Liu HF, Chu CC, et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis. 2007;28:1237–40.PubMedCrossRef

18.

Xiong YH, He L, Fei J. Genetic variations in cytotoxic T-lymphocyte antigen-4 and susceptibility to cervical cancer. Int Immunopharmacol. 2014;18:71–6.

19.

Wang L, Li D, Fu Z, Li H, Jiang W. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer. 2007;7:173.PubMedCrossRefPubMedCentral

20.

Welsh MM, Applebaum KM, Spencer SK, Perry AE, Karagas MR, Nelson HH. CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res. 2009;69:6158–63.PubMedCrossRefPubMedCentral

Title: Meta-analysis of the cytotoxic T-lymphocyte antigen 4 gene +6230G/A polymorphism and cancer risk
Authors: H.-Y. Zhao
H.-X. Duan
Y. Gu
Publication date: 01-10-2014
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 10/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1159-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2014

New biological markers in the decision of treatment of head and neck cancer patients

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

Subcutaneous trastuzumab: drug development and current position

Aldehyde dehydrogenases in early stage lung cancer: nuclear expression

Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer